Viability (indirect, secondary to IAPP amyloid toxicity): • Reduced amyloid aggregation (treatment with EVs from islets of healthy donors) • Increased amyloid aggregation (treatment with EVs from islets of T2DM donors) • Altered ratio of lipids to proteins in EVs from T2DM donors. This evidence concerns the gene IAPP and type 2 diabetes mellitus.